Literature DB >> 23179857

Applications of minimal physiologically-based pharmacokinetic models.

Yanguang Cao1, William J Jusko.   

Abstract

Conventional mammillary models are frequently used for pharmacokinetic (PK) analysis when only blood or plasma data are available. Such models depend on the quality of the drug disposition data and have vague biological features. An alternative minimal-physiologically-based PK (minimal-PBPK) modeling approach is proposed which inherits and lumps major physiologic attributes from whole-body PBPK models. The body and model are represented as actual blood and tissue (usually total body weight) volumes, fractions (f ( d )) of cardiac output with Fick's Law of Perfusion, tissue/blood partitioning (K ( p )), and systemic or intrinsic clearance. Analyzing only blood or plasma concentrations versus time, the minimal-PBPK models parsimoniously generate physiologically-relevant PK parameters which are more easily interpreted than those from mammillary models. The minimal-PBPK models were applied to four types of therapeutic agents and conditions. The models well captured the human PK profiles of 22 selected beta-lactam antibiotics allowing comparison of fitted and calculated K ( p ) values. Adding a classical hepatic compartment with hepatic blood flow allowed joint fitting of oral and intravenous (IV) data for four hepatic elimination drugs (dihydrocodeine, verapamil, repaglinide, midazolam) providing separate estimates of hepatic intrinsic clearance, non-hepatic clearance, and pre-hepatic bioavailability. The basic model was integrated with allometric scaling principles to simultaneously describe moxifloxacin PK in five species with common K ( p ) and f ( d ) values. A basic model assigning clearance to the tissue compartment well characterized plasma concentrations of six monoclonal antibodies in human subjects, providing good concordance of predictions with expected tissue kinetics. The proposed minimal-PBPK modeling approach offers an alternative and more rational basis for assessing PK than compartmental models.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23179857      PMCID: PMC3539784          DOI: 10.1007/s10928-012-9280-2

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  86 in total

1.  Single-dose pharmacokinetics of ampicillin and tobramycin administered by hypodermoclysis in young and older healthy volunteers.

Authors:  N Champoux; P Du Souich; M Ravaoarinoro; D Phaneuf; J Latour; J R Cusson
Journal:  Br J Clin Pharmacol       Date:  1996-09       Impact factor: 4.335

2.  Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment.

Authors:  S Riegelman; J C Loo; M Rowland
Journal:  J Pharm Sci       Date:  1968-01       Impact factor: 3.534

3.  Minimal compartmental model of circulatory mixing of indocyanine green.

Authors:  T K Henthorn; M J Avram; T C Krejcie; C A Shanks; A Asada; D A Kaczynski
Journal:  Am J Physiol       Date:  1992-03

4.  A recirculatory pharmacokinetic model describing the circulatory mixing, tissue distribution and elimination of antipyrine in dogs.

Authors:  T C Krejcie; T K Henthorn; C A Shanks; M J Avram
Journal:  J Pharmacol Exp Ther       Date:  1994-05       Impact factor: 4.030

5.  Pharmacokinetics of amoxicillin: Dosage nomogram for patients with impaired renal function.

Authors:  G Humbert; D A Spyker; J P Fillastre; A Leroy
Journal:  Antimicrob Agents Chemother       Date:  1979-01       Impact factor: 5.191

6.  Mezlocillin pharmacokinetics after single intravenous doses to patients with varying degrees of renal function.

Authors:  N Frimodt-Möller; S Maigaard; R D Toothaker; R W Bundtzen; M V Brodey; W A Craig; P G Welling; P O Madsen
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

7.  Comparative study of piperacillin, ticarcillin, and carbenicillin pharmacokinetics.

Authors:  B R Meyers; S Z Hirschman; L Strougo; E Srulevitch
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

8.  Cefoxitin pharmacokinetics: relation to three different renal clearance studies in patients with various degrees of renal insufficiency.

Authors:  D Kampf; R Schurig; I Korsukewitz; O Brückner
Journal:  Antimicrob Agents Chemother       Date:  1981-12       Impact factor: 5.191

9.  Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.

Authors:  Yvonne S Lin; Amy L S Dowling; Sean D Quigley; Federico M Farin; Jiong Zhang; Jatinder Lamba; Erin G Schuetz; Kenneth E Thummel
Journal:  Mol Pharmacol       Date:  2002-07       Impact factor: 4.436

10.  Modeling interindividual variability in physiologically based pharmacokinetics and its link to mechanistic covariate modeling.

Authors:  W Huisinga; A Solms; L Fronton; S Pilari
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2012-09-26
View more
  63 in total

Review 1.  Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.

Authors:  Jennifer E Sager; Jingjing Yu; Isabelle Ragueneau-Majlessi; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2015-08-21       Impact factor: 3.922

2.  Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies.

Authors:  Yanguang Cao; Joseph P Balthasar; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-08-31       Impact factor: 2.745

3.  An Extended Minimal Physiologically Based Pharmacokinetic Model: Evaluation of Type II Diabetes Mellitus and Diabetic Nephropathy on Human IgG Pharmacokinetics in Rats.

Authors:  Gurkishan S Chadha; Marilyn E Morris
Journal:  AAPS J       Date:  2015-08-15       Impact factor: 4.009

Review 4.  Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach.

Authors:  Kathryn Ball; François Bouzom; Jean-Michel Scherrmann; Bernard Walther; Xavier Declèves
Journal:  AAPS J       Date:  2013-06-20       Impact factor: 4.009

Review 5.  Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data.

Authors:  Nikolaos Tsamandouras; Amin Rostami-Hodjegan; Leon Aarons
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

6.  Modeling Combined Anti-Inflammatory Effects of Dexamethasone and Tofacitinib in Arthritic Rats.

Authors:  Ruihong Yu; Dawei Song; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  AAPS J       Date:  2019-07-24       Impact factor: 4.009

Review 7.  State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development.

Authors:  Venkata Yellepeddi; Joseph Rower; Xiaoxi Liu; Shaun Kumar; Jahidur Rashid; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2019-01       Impact factor: 6.447

8.  MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues.

Authors:  Silvia Maria Lavezzi; Enrica Mezzalana; Stefano Zamuner; Giuseppe De Nicolao; Peiming Ma; Monica Simeoni
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-11-10       Impact factor: 2.745

9.  Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling.

Authors:  Deni Hardiansyah; Chee Meng Ng
Journal:  MAbs       Date:  2018-07-30       Impact factor: 5.857

10.  Modeling Sex Differences in Anti-inflammatory Effects of Dexamethasone in Arthritic Rats.

Authors:  Dawei Song; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Pharm Res       Date:  2018-09-06       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.